Fatigue and sleep disturbances are symptoms of several chronic diseases associated with poor quality of life and increased healthcare costs. A large part of measuring patient’s health is using self-reported methods that can be prone to recall bias or require extensive effort to complete, e.g., sleep diaries. Building on these challenges, IDEA-FAST aims to determine “digital endpoints” or digital biomarkers through using multiple sensing devices “in-the-wild” to assess fatigue, sleep, and activities of daily living in patients with neurodegenerative diseases (e.g. Huntington’s disease) and immune-mediated inflammatory diseases (e.g. rheumatoid arthritis). IDEA-FAST is composed of three stages: a pre-feasibility process where multiple sensing devices were tested by experts and used with convenient subjects to select devices for the subsequent stage as detailed in; a feasibility study (FS) where eleven sensing devices were used “in-the-wild” by patients across six disease affliction groups; and a large-scale longitudinal study clinical observation study (COS) where a subset of devices from the FS will be used. The FS aims to identify candidate digital parameters of fatigue and sleep disturbances to be examined in the larger COS.
Read the full paper: https://dl.acm.org/doi/abs/10.1145/3460418.3479371